Search Result

Results for "

Glucokinase activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glucokinase (33) Drug Isomer (1) Insulin Receptor (1) mRNA (1) Reference Standards (1) Sodium Channel (1)
By Research Areas:	Cancer (2) Metabolic Disease (36) Neurological Disease (4)
Oligonucleotides:	mRNA (1)

Inhibitors & Agonists

Natural
Products

Oligonucleotides

Targets Recommended: Glucokinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144287

Glucokinase activator 3	Glucokinase Sodium Channel	Metabolic Disease
Glucokinase activator 3 is an orally active *Glucokinase* (GK) activator with an AC₅₀ of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .

HY-10595

RO-28-1675 3 Publications Verification	Glucokinase	Metabolic Disease
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC₅₀ of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes .

HY-100221

AM-2394	Glucokinase	Metabolic Disease
AM-2394 is a structurally distinct *glucokinase* activator (GKA). AM-2394 activates glucokinase (GK) with an EC₅₀ of 60 nM.

HY-156923

Glucokinase activator 5	Glucokinase	Metabolic Disease
Glucokinase activator 5 (compound 6) is a *glucokinase* activator .

HY-169545

Glucokinase activator 8	Glucokinase	Metabolic Disease
Glucokinase activator 8 is an activator for *glucokinase* .

HY-W997026

Glucokinase activator 7	Glucokinase	Metabolic Disease
Glucokinase activator 7 is a *Glucokinase* activator. Glucokinase activator 7 can be used for research of diabetes, hyperglycemia and other diseases (Compound in Page 176 of Ref.) .

HY-101788

Glucokinase activator 1	Glucokinase	Metabolic Disease
Glucokinase activator 1 is a liver-directed *glucokinase* activator with an EC₅₀ of 34 nM.

HY-116946

Glucokinase activator 6	Glucokinase	Metabolic Disease
Glucokinase activator 6 (compound 9) is a potent *glucokinase* activator, with an EC₅₀ of 0.09 μM. Glucokinase activator 6 can be used for type 2 diabetes (T2D) research .

HY-N14596

Glucolipsin A	Glucokinase	Metabolic Disease
Glucolipsin A is a *glucokinase* activator.

HY-N14597

Glucolipsin B	Glucokinase	Metabolic Disease
Glucolipsin B is a *glucokinase* activator.

HY-U00411

PSN-GK1	Glucokinase	Metabolic Disease
PSN-GK1 is a potent *glucokinase* activator with an EC₅₀ of 0.13 μM.

HY-116682

GKA-71	Glucokinase	Metabolic Disease
GKA-71 is an orally active *Glucokinase* activator, possesses an islet protective effect .

HY-P3257B

ADP-Specific glucokinase, thermococcus litoralis ADP-Dependent hexokinase, thermococcus litoralis	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, thermococcus litoralis is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, thermococcus litoralis can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, thermococcus litoralis can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, thermococcus litoralis can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-P3257A

ADP-specific glucokinase, pyrococcus furiosus ADP-dependent hexokinase, pyrococcus furiosus	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, pyrococcus furiosus is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, pyrococcus furiosus can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, pyrococcus furiosus can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, pyrococcus furiosus can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-100181

PF-04991532	Glucokinase	Metabolic Disease
PF-04991532 is a potent, hepatoselective *glucokinase* activator with EC₅₀s of 80 and 100 nM in human and rat, respectively.

HY-133127

AR453588	Glucokinase	Metabolic Disease
AR453588 is a potent and orally bioavailable anti-diabetic *glucokinase* activator, with an EC₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity .

HY-133127A

AR453588 hydrochloride	Glucokinase	Metabolic Disease
AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .

HY-19843

MK-0941	Glucokinase	Metabolic Disease
MK-0941 is a selective, orally active, and allosteric *glucokinase* activator with EC₅₀s of 240 and 65 nM for recombinant human *glucokinase* in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .

HY-100181B

(R)-PF-04991532	Drug Isomer	Metabolic Disease
(R)-PF-04991532 is the R-enantiomer of PF-04991532 (HY-100181). PF-04991532 is a potent, hepatoselective glucokinase activator .

HY-109030

Dorzagliatin 2 Publications Verification HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-19843A

MK-0941 free base	Glucokinase	Metabolic Disease
MK-0941 free base is an orally active *glucokinase* activator, with EC₅₀s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .

HY-15675

AZD1656	Glucokinase	Metabolic Disease
AZD1656 is a potent, selective and orally active *glucokinase* activator with an EC₅₀ of 60 nM. AZD1656 has the potential for type 2 diabetes research .

HY-119813

(S,S)-Sinogliatin (S,S)-HMS-5552; (S,S)-RO-5305552	Glucokinase	Metabolic Disease
(S,S)-Sinogliatin ((S,S)-HMS-5552) is the (S,S) -enantiomer of Sinogliatin. Sinogliatin is a *glucokinase* activator that can be used to study type 2 diabetes .

HY-121070

AZD1092	Glucokinase	Metabolic Disease
AZD1092 is an orally active glucokinase (GK) activator with an EC₅₀ value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D) .

HY-147254

Cadisegliatin TTP-399	Glucokinase	Metabolic Disease
Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for *glucokinase*, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-109030R

Dorzagliatin (Standard) HMS5552 (Standard)	Reference Standards Glucokinase	Metabolic Disease
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-108328

Nerigliatin PF-04937319	Glucokinase	Neurological Disease Metabolic Disease
Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC₅₀ value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial *glucokinase* (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-108328R

Nerigliatin (Standard)	Glucokinase	Neurological Disease Metabolic Disease
Nerigliatin (Standard) is the analytical standard of Nerigliatin. This product is intended for research and analytical applications. Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC50 value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent *glucokinase* activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-15671A

GKA50 quarterhydrate	Glucokinase	Metabolic Disease
GKA50 quarterhydrate is a potent *glucokinase* activator (EC₅₀=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats .

HY-13529

Globalagliatin 1 Publications Verification LY2608204; SY-004	Glucokinase	Metabolic Disease
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC₅₀ of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with an EC₅₀ of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .

HY-174547

Human PDX1 mRNA	mRNA	Metabolic Disease
Human PDX1 mRNA encodes the human pancreatic and duodenal homeobox 1 (PDX1) protein, a transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. PDX1 may be involved in the early development of the pancreas. It also plays a major role in glucose-dependent regulation of insulin gene expression.

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-177297

LCZ960 NVP-LCZ960	Glucokinase	Metabolic Disease
LCZ960 is an orally active *glucokinase* (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .

Peonidin 3-O-glucoside chloride 1 Publications Verification	Structural Classification Anthocyans Flavonoids Classification of Application Fields Source classification Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

Glucolipsin A	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification	Glucokinase
Glucolipsin A is a *glucokinase* activator.

Glucolipsin B	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification	Glucokinase
Glucolipsin B is a *glucokinase* activator.

Cat. No.	Product Name		Classification

HY-174547

Human PDX1 mRNA		mRNA
Human PDX1 mRNA encodes the human pancreatic and duodenal homeobox 1 (PDX1) protein, a transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. PDX1 may be involved in the early development of the pancreas. It also plays a major role in glucose-dependent regulation of insulin gene expression.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Glucokinase activator

Inhibitors & Agonists

NaturalProducts

Oligonucleotides

Natural
Products